#United States #Washington #Duchenne #PPMD #CINRG

PPMD and CINRG Collaboration

In a pivotal move towards improving treatment pathways for Duchenne muscular dystrophy (DMD), Parent Project Muscular Dystrophy (PPMD) recently announced its collaboration with the Cooperative International Neuromuscular Research Group (CINRG). This partnership marks a significant advancement in the expanded Duchenne Natural History Study (eDNHS), which aims to broaden our understanding of DMD and its progression.

A Deeper Dive into the eDNHS

The eDNHS is an extension of the original Duchenne Natural History Study conducted from 2005 to 2016. Sponsored by the University of California, Davis, the study is currently active and enrolling participants across ten sites globally, which include six locations in the United States, two in Canada, one in Australia, and one in India. This expansive geographical reach allows for a diverse range of data collection, which is crucial for understanding the varied manifestations of DMD.

Craig McDonald, MD, Co-Principal Investigator from the University of California, Davis, remarked, "We are thrilled that PPMD and six sponsors in the Duchenne therapeutic development space have joined together to advance our understanding of how Duchenne progresses in boys and men with Duchenne." Dr. McDonald emphasized the importance of collecting this data as new therapies become available, noting the necessity to understand their impact, thereby improving care for families affected by DMD.

Why Participate?

Participation in the eDNHS is open to boys and men diagnosed with Duchenne, irrespective of their current functional status or past participation in clinical trials. This inclusivity ensures that a wide array of experiences and progressions of the disease is represented. The study routinely conducts visits approximately every six months, synchronized with standard care schedules. Participants will undergo comprehensive evaluations, including questionnaires, medical history reviews, and strength and function testing, contributing invaluable information for future therapies.

To enhance community awareness and understanding of the study, PPMD will host a webinar on Wednesday, April 1st from 1:00 PM to 2:00 PM EST. This outreach initiative exemplifies their commitment to involving the community and providing vital information related to Duchenne muscular dystrophy.

About PPMD and Its Mission

PPMD is a leading non-profit organization devoted to combating Duchenne muscular dystrophy by advocating for optimal care standards and ensuring families have access to groundbreaking treatments and a supportive community. Since its inception in 1994, PPMD has tirelessly fought for the rights of those affected by Duchenne, advocating for research funding and significant FDA approvals that have directly benefited patients. Through their unwavering efforts, PPMD seeks to improve the quality of life for individuals with Duchenne and ultimately eradicate the condition for future generations.

The Role of CINRG

The Cooperative International Neuromuscular Research Group (CINRG) stands as a consortium of dedicated medical and scientific professionals actively engaged in enhancing the lives of neuromuscular disease patients through meticulously designed clinical studies. For those interested in learning more about the collaborative efforts between PPMD and CINRG, further details can be found on their official website.

This partnership represents a stepping stone towards a brighter future for those impacted by DMD, showcasing the power of collaboration in advancing medical research and improving patient outcomes.